Richard Duff, MD
Pulmonary Disease · Myrtle Beach, SCNPI 1447392444
Payments from drug & device makers
Across 60 payments — averaging $52.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- GSK$344
- TELA Bio, Inc.$173
- Inari Medical, Inc.$146
- Stryker$142
- Insmed, Inc.$126
- plus $585 from 19 others
What the payments were for
- Travel & lodging$1,54049%
- Food & beverage$1,48347%
- Education$1304%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $1,636 |
| GSK | 15 | $344 |
| TELA Bio, Inc. | 1 | $173 |
| Inari Medical, Inc. | 1 | $146 |
| Stryker | 1 | $142 |
| Insmed, Inc. | 3 | $126 |
| Actelion Pharmaceuticals US, Inc. | 4 | $88 |
| Sanofi | 4 | $83 |
| AstraZeneca | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Mylan Specialty L.p. | 2 | $43 |
| Shire North American Group Inc | 2 | $43 |
| Merck | 2 | $30 |
| Pfizer | 1 | $24 |
| United Therapeutics Corporation | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Amgen | 1 | $18 |
| Resmed Corp | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Novartis | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
| Biomerieux Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,153 in reported general payments places this provider in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $16,303 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,463 |
| EliquisApixaban | 20 | $7,333 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,213 |
| SynthroidLevothyroxine Sodium | 11 | $544 |
| Montelukast Sodium | 25 | $468 |
| Duloxetine Hcl | 19 | $430 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $331 |
| Omeprazole | 32 | $327 |
| Baclofen | 13 | $285 |
| Levothyroxine Sodium | 24 | $242 |
| Memantine Hcl | 16 | $240 |
| Tamsulosin Hcl | 18 | $237 |
| Furosemide | 23 | $209 |
| ClopidogrelClopidogrel Bisulfate | 20 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $344 | $28,76637 claims |
| PfizerEliquis | $24 | $7,33320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Myrtle Beach
- Adam BostickMyrtle Beach$38K
- Alan CohenMyrtle Beach$12K
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- Charles ThompsonAnderson$7.7M
- David ErbSpartanburg$7.5M
- Richard BoganColumbia$4.8M
- Patrick FlumeCharleston$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.